SYMIK-625 is a potent antibiotic formulation containing Amoxicillin Trihydrate IP 500 mg and Potassium Clavulanate Diluted IP 125 mg, tailored for combating a wide range of bacterial infections. By combining Amoxicillin, a reliable penicillin-based antibiotic, with Potassium Clavulanate, which protects Amoxicillin from degradation by bacteria, SYMIK-625 enhances the effectiveness of this antibiotic against strains that exhibit resistance. This innovative approach is particularly valuable for treating infections affecting the ears, sinuses, lungs, skin, urinary tract, and dental infections, providing timely and effective therapy. SYMIK-625 addresses both common and complicated infections, offering healthcare professionals a trusted option in antimicrobial treatment regimens. Hospitals, drug retailers, and healthcare providers can depend on SYMIK-625 for its broad-spectrum efficacy and reliability in patient care.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Amoxicillin Trihydrate 500 mg + Potassium Clavulanate 125 mg |
| Formulation Type | Combination Antibiotic |
| Target Infections | Respiratory Tract, Urinary Tract, Skin, Ears, Dental |
| Mechanism of Action | Inhibits bacterial cell wall synthesis and prevents degradation of Amoxicillin |
| Resistance Mitigation | Effective against resistant bacterial strains |
| Usage | Oral administration |
| Packaging | Available in blister packs for easy dispensing |
| Attributes | Description |
|---|---|
| Chemical Composition | Amoxicillin Trihydrate 500 mg, Potassium Clavulanate 125 mg |
| Dosage Form | Tablets |
| Strength | 625 mg per tablet |
| Indications | Bacterial infections of the ears, lungs, urinary tract, skin and teeth |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | 24 months from the date of manufacture |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
SYMIK-625 is effective in treating infections in the ears, sinuses, lungs, skin, urinary tract, and dental infections.
Potassium Clavulanate protects Amoxicillin from being broken down by beta-lactamase-producing bacteria, allowing Amoxicillin to act effectively against a wider range of resistant bacterial strains.
The recommended dosage depends on the specific infection and patient condition; however, it typically adheres to medical guidelines for Amoxicillin and Clavulanate combinations.
SYMIK-625
Amoxicillin Trihydrate IP 500 mg + Potassium Clavulanate Diluted IP 125 mg
SYMIK-625 combines Amoxicillin, a penicillin-based antibiotic, with Potassium Clavulanate, which helps protect Amoxicillin from being broken down by bacteria. This powerful duo allows Amoxicillin to work effectively against a wider range of bacteria, including those that have developed resistance to Amoxicillin alone. SYMIK-625 is commonly used to treat infections in the ears, sinuses, lungs, skin, urinary tract, and teeth.
SYMIK-625 is an effective combination antibiotic designed to combat bacterial infections. Amoxicillin works by attacking bacterial cell walls, while Potassium Clavulanate prevents bacteria from breaking down Amoxicillin, making it more effective against resistant strains. This combination helps fight infections in various areas, including the respiratory tract, urinary tract, skin, ears, and dental infections. SYMIK-625 provides a reliable solution for a broad spectrum of bacterial infections, ensuring fast and effective treatment.
